See the DrugPatentWatch profile for Xeljanz
The price of Xeljanz XR can vary based on factors such as dosage, insurance coverage, and pharmacy. A 30-day supply of Xeljanz XR (11 mg) can range from approximately $4,000 to over $6,000 [1].
How can I get a discount on Xeljanz XR?
Several options may help reduce the out-of-pocket cost of Xeljanz XR. Patients with commercial or employer-sponsored insurance may be eligible for the Xeljanz Co-Pay Card program, which can offer savings as low as $10 per month, up to a maximum annual benefit [2]. This program has terms and conditions, and eligibility requirements apply. For those without insurance or with high deductibles, patient assistance programs may be available through the manufacturer to provide financial support [3]. Information on these programs is typically found on the drug's official website or through healthcare provider resources.
When does the Xeljanz XR patent expire?
Understanding patent exclusivity is key to anticipating potential cost changes due to generic competition. Patents for Xeljanz (tofacitinib citrate) and its extended-release formulation have faced challenges and litigation. As of late 2023, some patents related to tofacitinib citrate have been invalidated in certain legal proceedings [4]. The specific expiration dates and legal statuses of all relevant patents can be complex and are subject to ongoing legal developments. DrugPatentWatch.com provides detailed information on patent landscapes for various drugs, including Xeljanz [5].
What is Xeljanz XR used for?
Xeljanz XR is a Janus kinase (JAK) inhibitor medication used to treat moderate to severe active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults who have had an inadequate response or intolerance to other treatments [2]. It works by helping to reduce inflammation in the body.